A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Phase 1 Completed 12 enrolled Ascletis Pharmaceuticals Co., Ltd.

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.

Timeline

Start: 2018-01-15
Primary completion: 2018-04-09
Completion: 2018-04-09

Publications

Wu G, Zhou H, Wu J, Lv D, Wu L, Zhai Y, Lin M, Wu JJ, Shentu J. Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0060021. doi: 10.1128/AAC.00600-21. Epub 2021 Jul 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ravidasvir	Small molecule	50 mg	Oral
Subject	Ravidasvir	Small molecule	200 mg	Oral

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Summary

Timeline

Publications

Drugs

Indications